28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Levels of insulin-like growth factor I (IGF-I), a neuroprotective hormone, decrease in serum during aging, whereas amyloid-beta (Abeta), which is involved in the pathogenesis of Alzheimer disease, accumulates in the brain. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This article is a report on a study of the multidimensional predictors of caregiver burden in caregivers of individuals with dementia using nationally representative data. 1 key finding →
Participants: 302 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Change in eating behaviour was significantly more common in both of the frontotemporal dementia groups than in Alzheimer's disease. 2 key findings →
Participants: 23 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
For example, focal temporal lobe dysfunction is associated with a pure amnestic syndrome, very slow decline, with atrophy and neurofibrillary tangles limited largely to the medial temporal region including the entorhinal cortex. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Intracytoplasmic aggregation of alpha-synuclein protein as Lewy bodies in the brainstem neurons is diagnostic for Parkinson's disease, whereas if this process also occurs in the cortical neurons, it is considered pathognomonic for dementia with Lewy bodies. 2 key findings →
Participants: 904 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Caregiver characteristics rather than objective care needs of the patients tend to be responsible for the onset of depression. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Overall burden was greater among adult-child caregivers, especially those who lived with the patient and who had other family duties. 5 key findings →
Design: cross-sectional Participants: 251 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Disinhibition is a common behavioural symptom in frontotemporal dementia but its neural correlates are still debated. 3 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Caregivers of care recipients without dementia or disability accounted for the largest absolute number of helpers. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This longitudinal study of 196 caregiver/care receiver dyads was undertaken to determine the variables predictive of caregiver decision to institutionalize a dependent with dementia. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia with Lewy bodies is the second most common form of neurodegenerative dementia, yet scarce evidence is available about its prognosis and natural history, which are crucial to inform clinical practice and research. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Factors impacting on time to diagnosis vary with the stage of diagnosis in YOD. 4 key findings →
Participants: 47 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Serious events, as indicated by a hospital admission or death, are frequent following the short-term use of antipsychotic drugs in older adults with dementia. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Resources for Enhancing Alzheimer's Cargiver Health (REACH) project was designed to test promising interventions for enhancing family caregiving for persons with dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These data show an individually varying complex convergence of subclinical diseases in the brain of older CN adults. 2 key findings →
Participants: 1,672 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Elderly co-resident caregivers for stroke and dementia patients experience similar degrees of burden and high levels of psychological morbidity. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The following strategies helped with implementation of decisions: introducing change slowly; organising legal changes for the carer as well as the patient; involving a professional to persuade the patient to accept services; and emphasising that services optimised, not impeded, independence. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The estimated total annual costs of dementia in China increased from 0.9 billion United States dollars (US$) in 1990 to US$ 47.2 billion in 2010 and were predicted to reach US$ 69.0 billion in 2020 and US$ 114.2 billion in 2030. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Minority Aging Research Study (MARS) is a longitudinal, epidemiologic cohort study of decline in cognitive function and risk of Alzheimer's disease (AD) in older African Americans, with brain donation after death added as an optional component for those willing to consider organ donation. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There is considerable variation in the phenotypic appearance of individuals with idiopathic Parkinson's disease (PD), which may translate into differences in disease progression in addition to underlying disease etiology. 5 key findings →
Participants: 162 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The prevalence of ICAS in older adults is high, and it could be a target for primary prevention of stroke and dementia in this population. 3 key findings →
Participants: 1,765 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The two overarching themes lend themselves to interventions at a service level and a community level which need to happen in synergy. 1 key finding →
Participants: 25,000 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We surveyed 1,545 subjects--recruited into the UK Medical Research Council elderly hypertension treatment trial between 1982 and 1987--to detect incident cases of dementia, identifying 50 cases of dementia, including 31 cases of probable or possible Alzheimer's disease (AD). 2 key findings →
Participants: 1,545 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
African Americans have higher incidence of, and mortality from, many health-related problems than European Americans. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Reduced ED attendances in the first wave of the pandemic suggest opportunities for reducing low severity presentations to ED in the future, but also raise the possibility of harm from delayed or missed care. 4 key findings →
Participants: 243,667 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →